Overview of Phase 3 EMERALD Study of Elacestrant for ER+, HER2–- MBC

Along with the Oncology Brothers, Paolo Tarantino, MD, provides an overview of the pPhase 3 EMERALD study, which evaluates the efficacy of elacestrant as a second-line treatment for ER+/HER2–- metastatic breast cancer, particularly in patients with ESR1 mutations.

Now Viewing

EP: 1.Overview of Phase 3 EMERALD Study of Elacestrant for ER+, HER2–- MBC

EP: 2.Incidence of ESR1 mutations and best practices for testing

Please give a brief overview of the phase 3 EMERALD study

Recent Videos